Given the critical importance of endocytosis detection in ADC research and development, ACROBiosystems has designed an ...
Proceeds Fund the Clinical Development of TORL-1-23, Currently in a Registrational Phase 2 Study for Claudin 6 Positive (CLDN6+) Platinum-Resistant Ovarian Cancer and in Phase 1 for other CLDN6+ ...
A new year means a new Fierce Biotech Fundraising Tracker to record the significant amounts of venture capital being funneled into the industry. We're maintaining the criteria we used for last year's ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback